ED
ONC

Exane Derivatives’s BeOne Medicines Ltd ONC Stock Holding History

Exane Derivatives’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-311
Closed -$113K – 1092
2021
Q3 		$113K Buy
311
+72
+30% +$23.5K 0.03% 506
2021
Q2 		$79K Sell
239
-126
-35% -$41.7K 0.02% 573
2021
Q1 		$127K Sell
365
-475
-57% -$157K 0.04% 380
2020
Q4 		$217K Buy
840
+80
+11% +$22K 0.06% 302
2020
Q3 		$218K Buy
760
+10
+1% +$2.35K 0.06% 207
2020
Q2 		$141K Hold
750
– – 0.04% 242
2020
Q1 		$92.3K Buy
+750
New +$117K 0.03% 289

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Exane Derivatives's ONC Position: Q4 2021 in Review

Exane Derivatives sold out of BeOne Medicines Ltd (ONC) in Q4 2021, closing a stake of 311 shares — an estimated $113K sold.

Exane Derivatives first reported a position in ONC in Q1 2020 and held it in 7 quarters. The position peaked at $218K in Q3 2020. 263 funds tracked by Wall St. Rank hold ONC as of Q4 2021.

  • Exane Derivatives reported no remaining BeOne Medicines Ltd position as of Q4 2021 after selling out during the quarter.
  • Exane Derivatives sold 311 BeOne Medicines Ltd shares in Q4 2021, an estimated $113K.
  • Exane Derivatives first reported a position in BeOne Medicines Ltd in Q1 2020 and held it in 7 quarters.
  • Exane Derivatives's BeOne Medicines Ltd position peaked at $218K in Q3 2020.
  • 263 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.